Harry Gillis
Stock Analyst at Berenberg Bank
(4.58)
# 977
Out of 4,698 analysts
95
Total ratings
78.3%
Success rate
22.8%
Average return
Main Sectors:
Stocks Rated by Harry Gillis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintained: Hold | $1,220 | $1,160.08 | +5.17% | 1 | Aug 13, 2026 | |
| SWX: TECN Tecan Group AG | Maintained: Buy | CHF 220.00 | CHF 196.00 | +12.24% | 13 | Aug 12, 2026 | |
| QGEN Qiagen | Maintained: Hold | $46 | $44.20 | +2.94% | 10 | Aug 6, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $140 → $132 | $103.81 | +27.16% | 13 | Aug 5, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 575.00 → kr 560.00 | kr 455.00 | +23.08% | 26 | Aug 3, 2026 | |
| MRNA Moderna | Maintained: Hold | $45 | $150.81 | -70.16% | 12 | Jul 31, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Buy | €270.00 | €246.00 | +9.76% | 6 | Jul 30, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | $14 → $7.45 | $7.35 | +1.36% | 14 | Jul 20, 2026 |
Eli Lilly and Company
Aug 13, 2026
Maintained: Hold
Price Target: $1,220
Current: $1,160.08
Upside: +5.17%
Tecan Group AG
Aug 12, 2026
Maintained: Buy
Price Target: CHF 220.00
Current: CHF 196.00
Upside: +12.24%
Qiagen
Aug 6, 2026
Maintained: Hold
Price Target: $46
Current: $44.20
Upside: +2.94%
BioNTech SE
Aug 5, 2026
Maintained: Buy
Price Target: $140 → $132
Current: $103.81
Upside: +27.16%
Swedish Orphan Biovitrum AB (publ)
Aug 3, 2026
Maintained: Buy
Price Target: kr 575.00 → kr 560.00
Current: kr 455.00
Upside: +23.08%
Moderna
Jul 31, 2026
Maintained: Hold
Price Target: $45
Current: $150.81
Upside: -70.16%
Sartorius Aktiengesellschaft
Jul 30, 2026
Maintained: Buy
Price Target: €270.00
Current: €246.00
Upside: +9.76%
AtaiBeckley
Jul 20, 2026
Downgraded: Hold
Price Target: $14 → $7.45
Current: $7.35
Upside: +1.36%